Brought to you by 
Cerenis brings in €50mm via its Series C round
21 Oct 2010
Executive Summary
Cerenis Therapeutics SA (cardiovascular and metabolic conditions) has raised €40mm ($51.9mm) through the first closing of its Series C venture round. The Fund for Strategic Investment provided €20mm and the remainder came from current shareholders Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, EDF Ventures, OrbiMed, and Daiwa Corporate Investment. The money will be used to continue developing Phase II CER001 for cardiovascular disease and to work on other HDL drug candidates. The same day it announced the Series C round, Cerenis received €10.7mm from the French government.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com